Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XenoPort’s Second Pain Failure Puts Heat On Restless Legs

This article was originally published in The Pink Sheet Daily

Executive Summary

With generic Requips making headway in restless legs, investors had counted on cashing in on diabetic neuropathy.

You may also be interested in...



Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA

An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.

Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA

An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.

Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA

The news that FDA rejected GlaxoSmithKline/XenoPort's NDA for Horizant (gabapentin enacarbil) for restless leg syndrome due to a carcinogenicity signal in rats took Wall Street by surprise and crushed XenoPort, which lost more than half its market value Feb. 18. The companies issued a press release announcing receipt of an FDA "complete response" letter for Horizant after the market closed on Feb. 17

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel